HDAC3 inhibition offers the potential to block the BCL6-HDAC3 complex and restore the key pathways in cell cycle and differentiation inhibited by BCL6 in CREBBP-mutant lymphomas, including Ag presentation as well as BCR, NF-kB, and interferon signaling (Mondello et al., 2020). Here, HDAC3 is linked to lymphoma.